Effect of silencing SATB1 on proliferation, invasion and apoptosis of A549 human lung adenocarcinoma cells

Huang,Bo; Zhou,Hongli; Wang,Siwang; Lang,Xian  Ping; Wang,Xiaodong

doi:10.3892/ol.2016.5179

Effect of silencing SATB1 on proliferation, invasion and apoptosis of A549 human lung adenocarcinoma cells

Authors:
- Bo Huang
- Hongli Zhou
- Siwang Wang
- Xian Ping Lang
- Xiaodong Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China, Department of Kidney Diseases, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: September 22, 2016 https://doi.org/10.3892/ol.2016.5179
Pages: 3818-3824
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the clinical characteristics of special adenine‑thymine‑rich sequence‑binding protein 1 (SATB1) in lung adenocarcinoma and its role in the proliferation, invasion, migration and apoptosis of the lung adenocarcinoma cell line A549. The expression of SATB1 was first studied in tumor tissues of lung adenocarcinoma and adjacent non‑tumor tissues. The siRNA green fluorescent protein expression vector of SATB1 was constructed and transfected into the lung adenocarcinoma cell line A549, then a fluorescence microscope was used to study the transfection efficiency. Western blot analysis was adopted to measure the silencing efficiency. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Transwell and scratch assays were used to study cell proliferation, invasion and migration activity, and the apoptosis rate was tested by flow cytometry. SATB1 expression was low in the adjacent non‑tumor tissues but high in lung adenocarcinoma tissues, and it was reversely proportional to the differentiation degree. Following transfection with SATB1‑siRNA, the expression of SATB1 in A549 cells was blocked (P<0.01). In addition, the proliferation, invasion and migration abilities of cells decreased significantly while the apoptosis rate increased significantly (P<0.01). In conclusion SATB1 is closely associated with the pathogenesis and development of lung adenocarcinoma.

View Figures

View References

1	Yatabe Y, Borczuk AC and Powell CA: Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer. 74:7–11. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kadara H, Kabbout M and Wistuba II: Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology. 17:50–65. 2012. View Article : Google Scholar : PubMed/NCBI
3	Xu L, Deng HX, Xia JH, Yang Y, Fan CH, Hung WY and Siddque T: Assignment of SATB1 to human chromosome band 3p23 by in situ hybridization. Cytogenet Cell Genet. 77:205–206. 1997. View Article : Google Scholar : PubMed/NCBI
4	Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, et al: Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol. 12:898–907. 2011. View Article : Google Scholar : PubMed/NCBI
5	Han HJ, Russo J, Kohwi Y and Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 452:187–193. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B, Zhao M, Wei M, Ye C, Sun Y, et al: Expression of SATB1 promotes the growth and metastasis of colorectal cancer. PLoS One. 9:e1004132014. View Article : Google Scholar : PubMed/NCBI
7	Han B, Luan L, Xu Z and Wu B: Expression and biological roles of SATB1 in human bladder cancer. Tumour Biol. 34:2943–2949. 2013. View Article : Google Scholar : PubMed/NCBI
8	Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D and Gupta S: Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. PLoS One. 8:e535272013. View Article : Google Scholar : PubMed/NCBI
9	Zuk K, Peczek L, Stec-Michalska K, Medrek M and Nawrot B: SATB1 expression in gastric mucosa in relation to Helicobacter pylori infection and family history of gastric cancer. Adv Med Sci. 57:237–243. 2012. View Article : Google Scholar : PubMed/NCBI
10	Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH and Goldstraw P: IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:694–705. 2007. View Article : Google Scholar : PubMed/NCBI
11	Notsuda H, Sakurada A, Endo C, Okada Y, Horii A, Shima H and Kondo T: p190A RhoGAP is involved in EGFR pathways and promotes proliferation, invasion and migration in lung adenocarcinoma cells. Int J Oncol. 43:1569–1577. 2013.PubMed/NCBI
12	Keaney J, Campbell M and Humphries P: From RNA interference technology to effective therapy: how far have we come and how far to go? Ther Deliv. 2:1395–1406. 2011. View Article : Google Scholar : PubMed/NCBI
13	Xia L, Guan W, Wang D, Zhang YS, Zeng LL, Li ZP, Wang G and Yang ZZ: Killing effect of Ad5/F35-APE1 siRNA recombinant adenovirus in combination with hematoporphrphyrin derivative-mediated photodynamic therapy on human nonsmall cell lung cancer. Biomed Res Int. 2013:9579132013. View Article : Google Scholar : PubMed/NCBI
14	Yi X, Zhao G, Zhang H, Guan D, Meng R, Zhang Y, Yang Q, Jia H, Dou K, Liu C, et al: MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther. 19:362–371. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hanker LC, Karn T, Mavrova-Risteska L, Ruckhäberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A and Wiegratz I: SATB1 gene expression and breast cancer prognosis. Breast. 20:309–313. 2011. View Article : Google Scholar : PubMed/NCBI
16	Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C and Kohonen-Corish MR: Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 6:1179–1189. 2011. View Article : Google Scholar : PubMed/NCBI
17	Huang B, Zhou H, Wang X and Liu Z: Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 13:82013. View Article : Google Scholar : PubMed/NCBI
18	Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr, Barnas JL, Simpson-Abelson M, Parsons R and Yokota SJ: Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 6:e244202011. View Article : Google Scholar : PubMed/NCBI
19	Fang XF, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, Li XF, Yu LK and Yuan Y: Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 19:2331–2339. 2013. View Article : Google Scholar : PubMed/NCBI
20	Cai S, Han HJ and Kohwi-Shigematsu T: Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 34:42–51. 2003. View Article : Google Scholar : PubMed/NCBI
21	Mir R, Pradhan SJ and Galande S: Chromatin organizer SATB1 as a novel molecular target for cancer therapy. Curr Drug Targets. 13:1603–1615. 2012. View Article : Google Scholar : PubMed/NCBI